Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MONET: RSVpreF in adults at high risk of severe RSV disease
NCT05842967Phase 3Completed
- Sponsor
- Pfizer
- Start
- May 2023
- Primary completion
- Mar 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of RSVpreF vaccine in respiratory syncytial virus infection (RSV), sponsored by Pfizer. Started May 2023; status: completed.
02
Drugs
RSVpreF vaccine
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT05842967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05842967.